JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma.
Toshihiko WakabayashiAtsushi NatsumeJunki MizusawaHiroshi KatayamaHaruhiko FukudaMinako SumiRyo NishikawaYoshitaka NaritaYoshihiro MuragakiTakashi MaruyamaTamio ItoTakaaki BeppuHideo NakamuraTakamasa KayamaShinya SatoMotoo NaganeKazuhiko MishimaYoko NakasuKaoru KurisuFumiyuki YamasakiKazuhiko SugiyamaTakanori OnishiYasuo IwadateMizuhiko TerasakiHiroyuki KobayashiAkira MatsumuraEiichi IshikawaHikaru SasakiAkitake MukasaTakayuki MatsuoHirofumi HiranoToshihiro KumabeNobusada ShinouraNaoya HashimotoTomokazu AokiAkio AsaiTatsuya AbeAtsuo YoshinoYoshiki ArakawaKenichiro AsanoKoji YoshimotoSoichiro Shibuinull nullPublished in: Journal of neuro-oncology (2018)
TMZ + IFNβ + RT is not considered as a candidate for the following phase III trial, and TMZ + RT remained to be a most promising treatment. This trial was registered with the UMIN Clinical Trials Registry: UMIN000003466.